BioCentury
ARTICLE | Finance

Regulatory Milestones

Highlights of weekly biotech stock moves

June 28, 2010 7:00 AM UTC

Celgene Corp. (NASDAQ:CELG) gained $0.72 to $56.07 last week after Japan's Ministry of Health, Labor and Welfare (MHLW) approved Revlimid lenalidomide in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM).

Genmab A/S (CSE:GEN) was off DKK9.35 (15%) to DKK51.65 last week after the U.K.'s NICE issued a preliminary appraisal recommending against the use of Arzerra ofatumumab to treat chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. The mAb against CD20 is partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) (see Online Links, A20)...